唑来膦酸对预防腰椎PVP术后再发骨折的疗效评价

doi:10.3969/j.issn.1000-8535.2021.03.011

摘要/Abstract

摘要： 目的比较唑来膦酸对 PVP(椎体成形术)治疗OVCF(骨质疏松椎体压缩性骨折)术后再发骨折的影响。方法收集2016年12月—2018年6月在我院骨科接受PVP治疗患者共70例,其中40人在术后接受了唑来膦酸治疗(观察组),30人在术后接受了安慰剂治疗(对照组),两组患者均给予维生素D和钙剂基础治疗。记录术后6个月、1年、2年腰椎骨密度;术后2年内伤椎及邻近椎体再发骨折情况。结果观察组伤椎再发骨折率(1/40,2.5%)低于对照组(2/30,6.67%)(P＜0.05);观察组邻椎再发骨折率(2/40,5%)低于对照组(7/30,23.33%)(P＜0.05)。结论唑来膦酸能较好地预防PVP术后再发骨折。

关键词: 唑来膦酸, 椎体成形术, 再发骨折

Abstract: Objective To compare the effect of zoledronic acid on the treatment of osteoporotic vertebral compression fracture after percutaneous vertebroplasty PVP. Methods From December 2017 to June 2019, a total of 70 patients who received PVP in the hospital medical plastic surgery clinic, 40 patients were collected received zoledronic acid (group A) and 30 patients received placebo (group B) after operation. Both groups received basic treatment of vitamin D and calcium. The bone mineral densits (BMD) of lumbar vertebrae were recorded at 6 months, 1 year and 2 years after operation, and the recurrent fractures of injured vertebrae and adjacent vertebrae were recorded at 2 years after operation. Results The rate of recurrent fracture of vertebrae in group A (1/40, 2.5%) was lower than that in group B (2/30, 6.67%); the rate of recurrent fracture of adjacent vertebrae in group A (2/40, 5%) was grcartly lower than that in group B (7/30, 23.33%). Conclusion Zoledronic acid can prevent recurrent fracture after PVP.

Key words: Zoledronic acid, PVP, Recurrent fracture

张强, 李文升, 冯良恩, 李瑞龙, 李峰. 唑来膦酸对预防腰椎PVP术后再发骨折的疗效评价[J]. 广州医药, 2021, 52(3): 52-55.

ZHANG Qiang, LI Wensheng, FENG Liangen, LI Ruilong, LI Feng. Effect of zoledronic acid on prevention of recurrent fracture after PVP[J]. Guangzhou Medical Journal, 2021, 52(3): 52-55.

参考文献

[1] GAMBACCIANI M,LEVANCINI M.Management of postmenopausal osteoporosis and the prevention offractures[J]. Panminerva Med,2014,56(2):115-131.
[2] 皮海菊,肖淼生,尚晖.经皮椎体后凸成形术治疗陈旧性骨质疏松椎体压缩性骨折疗效观察[J]. 中国临床研究,2017,30(1):27-30.
[3] YU W,XU W,JIANG X,et al. Risk factors for recollapse of theaugmented vertebrae after percutaneous vertebral augmentation: asystematic review and Meta-analysis[J]. World Neurosurg,2018(111):119-129.
[4] GOLDSTEIN C L,CHUTKAN N B,CHOMA T J,et al. Management of the elderly with vertebral compression fractures[J]. Neurosurgery,2015,77(4):S33-45.
[5] 刘新奇,叶福生,王永光,等. 唑来膦酸治疗老年患者经皮椎体后凸成形术后椎体再骨折的短期疗效[J]. 中华骨质疏松和骨矿盐疾病杂志,2015,8(1):4852.
[6] 石晨,程安源. 椎体后凸成形术联合唑来膦酸治疗骨质疏松性椎体骨折的疗效分析[C]. 中国中西医结合学会骨伤科专业委员会.2019楚天骨科高峰论坛暨第二十六届中国中西医结合骨伤科学术年会论文集.中国中西医结合学会骨伤科专业委员会:中国中西医结合学会,2019:257-258.
[7] 张觅,刘洋,谭俊峰,等. 经皮椎体后凸成形、唑来膦酸或两者联合治疗老年骨质疏松性腰椎椎体压缩性骨折的对比[J]. 中国组织工程研究,2019,23(16):2479-2485.
[8] 李瑞龙,李文升.腰椎融合术后腰痛与维生素D水平及腰椎骨密度的关系研究[J]. 华夏医学,2019,32(5):24-27.
[9] 李正,付军.唑来膦酸和特立帕肽对预防椎体成形术后再发骨折的疗效比较[J]. 中国骨质疏松杂志,2019,25 (7):1002-1005.
[10] SIRIS E S,ADLER R,BILEZIKIAN J,et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group [J]. Osteoporos Int,2014(25):1439-1443.
[11] 夏维波,章振林,林华,等. 原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志,2019,25(3):281-309.
[12] 李凯明,朱立国,张清,等. 唑来膦酸联合椎体后凸成形治疗骨质疏松性压缩骨折:提高骨密度、预防椎体再骨折、远期疗效评价的Meta分析[J]. 中国组织工程研究,2020,24(24):3911-3917.
[13] 蓝涛,陈扬,杨欣建.椎体成形术后再骨折研究进展[J]. 中国脊柱脊髓杂志,2015,25(2):179-182.
[14] ZHANG H,XU C,ZHANG T,et al.Does percutaneous vertebroplasty or balloon kyphoplasty for osteoporotic vertebralcompression fractures increase the incidence of new vertebralfractures? a Meta-analysis[J]. Pain Physician,2017,20(1):13-28.
[15] 卢昌怀,刘志军,张宏波,等. 骨水泥量及分布对椎体成形术后相邻椎体生物力学影响的三维有限元分析[J]. 中国骨质疏松杂志,2015,21(1):29-33.
[16] 叶向阳,汤立新,程省,等. 骨密度对骨质疏松性椎体压缩性骨折PKP术后骨折再发风险的评估价值[J]. 中国骨质疏松杂志,2017,23(2):154-158.
[17] COMPSTON J,COOPER A,COOPER C,et al.UK clinical guideline for the prevention and treatment of osteoporosis [J]. Arch Osteoporos,2017,12(1):40-43.
[18] 高雷,任艳,高华增.唑来膦酸对骨质疏松骨含量的影响[J]. 中国骨质疏松杂志,2015,21(1):72-74.
[19] 王丹.美国FDA扩大唑来膦酸适应症[N]. 2008.09.15.
[20] BELL K J, HAYEN A, GLASZIOU P, et al. Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis:secondary analysis of randomized controlled trial data[J]. Bone Miner Res,2016,31(9): 1767-1773.
[21] ROBERT A A,GHADA E F,DOUGLAS C B, et al. Managing osteoporosis in patients on long‐term bisphosphonate treatment: report of a task force of the american society for bone and mineral research[J]. Bone Mine Res,2016,31(10).
[22] YOO C M,PARK K B,HWANG S H,et al。The analysis of patterns and risk factors of newly developed vertebral compression fractures after percutaneous veteroplasty[J]. J Korean Neurosurg Soc,2016,52(4):339-345.
[23] 张煜,张绍东.椎体成形术后手术椎体再塌陷的危险因素[J]. 中国脊柱脊髓杂志,2016,26(5):459-462.
[24] 秦德安,宋洁富,邵晋康,等. 骨质疏松性椎体压缩骨折椎体成形术后再骨折分析[C]. 中华医学会、中华医学会骨质疏松和骨矿盐疾病分会.中华医学会第七次全国骨质疏松和骨矿盐疾病学术会议论文汇编.中华医学会,2013:100.
[25] 王小健,苏云星,宋洁富,等. 老年骨质疏松性椎体压缩骨折经皮椎体成形术后继发骨折相关因素的Meta分析[J]. 中华创伤骨科杂志,2017,19(9):782-790.